title: [Comparative plasma proteomic analysis of patients with multiple myeloma treated with bortezomib-based regimens].
abstract: BACKGROUND
  Recently, the term biomarker has become, especially in connection with the term clinical proteomics, one of the most frequent terms in the field of biomedical research. The aim of this work was to select an appropriate pre-fractionation method of blood plasma prior to a subsequent proteomic analysis of low-abundant fraction of proteins by two dimensional gel electrophoresis (2-DE) and mass spectrometry to improve the resolution of 2-DE maps and protein identification.
  
  
  METHODS
  First, we compared two prefractionation methods (MARS versus ProteoMiner) preceding 2-DE analysis using 10 blood plasma samples. Based on the results of the comparative experiments, low-abundant plasma protein fractions from 18 multiple myeloma patients treated with bortezomib were analyzed. Patients were divided into two groups: a group resistant to chemotherapy (9 patients--disease progression, stable disease) and a group with positive clinical response (9 patients--complete and partial remission).
  
  
  CONCLUSIONS
  Samples prefractioned by ProteoMiner method yielded 2-DE maps with a significantly increased number of detected protein spots, as compared to immunodepletion method MARS (Multiple Affinity Removal System). Between groups of chemoresistant and sensitive patients treated with bortezomib, 15 differently intense spots were revealed by image analysis. These spots were found to correspond to 10 proteins, as confirmed by mass spectrometry. Seven proteins had significantly lower protein level in the group of chemosensitive patients (serum amyloid P, fibrinogen--gamma chain, retinol-binding protein 4, complement factor C4-A, apolipoprotein E, carboxypeptidase N and complement factor H-related protein 1) and 3 proteins showed significantly higher levels of protein (or were only detected) in the group of chemosensitive patients (serum paraoxonase 1, alpha-1-antitrypsin and complement factor B).
authors.affiliation: Babákova myelomová skupina, Ústav patologické fyziologie, LF MU Brno.
authors.forename: J
authors.initials: J
authors.lastname: Cumová
authors.forename: L
authors.initials: L
authors.lastname: Jedličková
authors.forename: D
authors.initials: D
authors.lastname: Potěšil
authors.forename: O
authors.initials: O
authors.lastname: Sedo
authors.forename: K
authors.initials: K
authors.lastname: Stejskal
authors.forename: A
authors.initials: A
authors.lastname: Potáčová
authors.forename: Z
authors.initials: Z
authors.lastname: Zdráhal
authors.forename: R
authors.initials: R
authors.lastname: Hájek
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins / Q000032:analysis*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D015180:Electrophoresis, Gel, Two-Dimensional; D005260:Female; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy*; D040901:Proteomics; D011719:Pyrazines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D001798:Blood Proteins; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib